Drugs / TOL-3021
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03794960 | Dec 2019 → Dec 2021 | type 1 diabetes mellitus | Tolerion, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03794973 | Dec 2019 → Dec 2021 | type 1 diabetes mellitus | Tolerion, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03895437 | Jun 2019 → Dec 2020 | type 1 diabetes mellitus | Tolerion, Inc. | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOL-3021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03895437 ↗ |
| Modality | Other / unclassified | “A plasmid expression vector containing the coding sequences for full-length human proinsulin.” NCT03794960 ↗ |
| Route | Intramuscular | “Study drug treatments will be administered via an intramuscular (IM) injection into a large muscle every week for 52 weeks.” NCT03895437 ↗ |